Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Heart Attack Diagnostics Market by Type (Electrocardiogram, Blood Tests, Angiogram, Computerized Cardiac Tomography, Others), by End User (Hospitals, Diagnostics Centers, Others) : Global Opportunity Analysis and Industry Forecast, 2024 - 2033

A12689

Pages: 260

Charts: 57

Tables: 111

Heart Attack Diagnostics Market Overview

The global heart attack diagnostics market size was valued at $9.2 billion in 2023, and is projected to reach $21.1 billion by 2033, growing at a CAGR of 8.6% from 2024 to 2033. Rising global prevalence of cardiovascular disease fueled by aging populations, unhealthy lifestyles, and chronic risk factors; and rapid technological innovation are major drivers of the market.    

Market Size & Future Outlook 

  • 2023 Market Size: $9.2 Billion 
  • 2033 Projected Market Size: $21.1 Billion 
  • CAGR (2024-2033): 8.6% 
  • North America: Largest market in 2023 
  • Asia Pacific: Fastest growing market 

The global heart attack diagnostics market is experiencing growth due to several factors such as increase in prevalence of cardiovascular diseases, technological advancement in diagnostic techniques, and growing awareness among both healthcare providers and patients about the importance of early detection and intervention in preventing adverse outcomes from heart attacks.

Market Introduction and Definition

Heart attack diagnostics involve a series of tests and evaluations aimed at determining whether an individual has experienced a myocardial infarction, commonly known as a heart attack. These diagnostics typically include an assessment of symptoms such as chest pain, shortness of breath, and nausea, along with the patient's medical history and risk factors such as smoking, hypertension, and diabetes. Diagnostic tests may include an electrocardiogram (ECG/EKG) to measure the heart's electrical activity, blood tests to check for cardiac enzymes such as troponin, which are released into the bloodstream when the heart muscle is damaged, and imaging tests such as echocardiography or coronary angiography to visualize the heart and its blood vessels.

Key Takeaways

  • The heart attack diagnostics market study covers 20 countries. The research includes a segment analysis of each country in terms of value for the projected period, 2024-2033.
  • More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major heart attack diagnostics industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
  • The study integrated high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach is intended to provide a balanced view of global markets and to assist stakeholders in making educated decisions in order to achieve their most ambitious growth objectives.

 Key Market Segments

  • By Type
    • Electrocardiogram
    • Blood Tests
    • Angiogram
    • Computerized Cardiac Tomography
    • Others
  • By End User
    • Hospitals
    • Diagnostics Centers
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • Bionet Co., Ltd
  • F. Hoffmann-La Roche Ltd.
  • Bio-Rad Laboratories Inc
  • Schiller AG
  • Abbott Laboratories
  • Life Sign LLC
  • Beckman Coulter,Inc.
  • GE Healthcare
  • Hitachi Medical Systems
  • TOSHIBA CORPORATION

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: HEART ATTACK DIAGNOSTICS MARKET, BY TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Type

    • 4.2. Electrocardiogram

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Blood Tests

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Angiogram

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Computerized Cardiac Tomography

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: HEART ATTACK DIAGNOSTICS MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Diagnostics Centers

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: HEART ATTACK DIAGNOSTICS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Heart Attack Diagnostics Market

        • 6.2.5.1. Market Size and Forecast, By Type
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Heart Attack Diagnostics Market

        • 6.2.6.1. Market Size and Forecast, By Type
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Heart Attack Diagnostics Market

        • 6.2.7.1. Market Size and Forecast, By Type
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Heart Attack Diagnostics Market

        • 6.3.5.1. Market Size and Forecast, By Type
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Heart Attack Diagnostics Market

        • 6.3.6.1. Market Size and Forecast, By Type
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Heart Attack Diagnostics Market

        • 6.3.7.1. Market Size and Forecast, By Type
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Heart Attack Diagnostics Market

        • 6.3.8.1. Market Size and Forecast, By Type
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Heart Attack Diagnostics Market

        • 6.3.9.1. Market Size and Forecast, By Type
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Heart Attack Diagnostics Market

        • 6.3.10.1. Market Size and Forecast, By Type
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Heart Attack Diagnostics Market

        • 6.3.11.1. Market Size and Forecast, By Type
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Heart Attack Diagnostics Market

        • 6.4.5.1. Market Size and Forecast, By Type
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Heart Attack Diagnostics Market

        • 6.4.6.1. Market Size and Forecast, By Type
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Heart Attack Diagnostics Market

        • 6.4.7.1. Market Size and Forecast, By Type
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Heart Attack Diagnostics Market

        • 6.4.8.1. Market Size and Forecast, By Type
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Heart Attack Diagnostics Market

        • 6.4.9.1. Market Size and Forecast, By Type
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Heart Attack Diagnostics Market

        • 6.4.10.1. Market Size and Forecast, By Type
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Heart Attack Diagnostics Market

        • 6.4.11.1. Market Size and Forecast, By Type
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Heart Attack Diagnostics Market

        • 6.4.12.1. Market Size and Forecast, By Type
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Heart Attack Diagnostics Market

        • 6.4.13.1. Market Size and Forecast, By Type
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Heart Attack Diagnostics Market

        • 6.5.5.1. Market Size and Forecast, By Type
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Heart Attack Diagnostics Market

        • 6.5.6.1. Market Size and Forecast, By Type
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Heart Attack Diagnostics Market

        • 6.5.7.1. Market Size and Forecast, By Type
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Heart Attack Diagnostics Market

        • 6.5.8.1. Market Size and Forecast, By Type
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Heart Attack Diagnostics Market

        • 6.5.9.1. Market Size and Forecast, By Type
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Heart Attack Diagnostics Market

        • 6.5.10.1. Market Size and Forecast, By Type
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Bionet Co., Ltd

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. TOSHIBA CORPORATION

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Bio-Rad Laboratories Inc

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Life Sign LLC

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Schiller AG

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Beckman Coulter,Inc.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. GE Healthcare

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Hitachi Medical Systems

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. F. Hoffmann-La Roche Ltd.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Abbott Laboratories

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL HEART ATTACK DIAGNOSTICS MARKET, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL HEART ATTACK DIAGNOSTICS MARKET FOR ELECTROCARDIOGRAM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL HEART ATTACK DIAGNOSTICS MARKET FOR BLOOD TESTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL HEART ATTACK DIAGNOSTICS MARKET FOR ANGIOGRAM, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL HEART ATTACK DIAGNOSTICS MARKET FOR COMPUTERIZED CARDIAC TOMOGRAPHY, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL HEART ATTACK DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL HEART ATTACK DIAGNOSTICS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL HEART ATTACK DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL HEART ATTACK DIAGNOSTICS MARKET FOR DIAGNOSTICS CENTERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL HEART ATTACK DIAGNOSTICS MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL HEART ATTACK DIAGNOSTICS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA HEART ATTACK DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 15. U.S. HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 16. U.S. HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 17. CANADA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 18. CANADA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE HEART ATTACK DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. ITALY HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 29. ITALY HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. UK HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 33. UK HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC HEART ATTACK DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. CHINA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 42. CHINA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. INDIA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 46. INDIA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA HEART ATTACK DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. UAE HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 69. UAE HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA HEART ATTACK DIAGNOSTICS, BY TYPE, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA HEART ATTACK DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. BIONET CO., LTD: KEY EXECUTIVES
  • TABLE 75. BIONET CO., LTD: COMPANY SNAPSHOT
  • TABLE 76. BIONET CO., LTD: OPERATING SEGMENTS
  • TABLE 77. BIONET CO., LTD: PRODUCT PORTFOLIO
  • TABLE 78. BIONET CO., LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. TOSHIBA CORPORATION: KEY EXECUTIVES
  • TABLE 80. TOSHIBA CORPORATION: COMPANY SNAPSHOT
  • TABLE 81. TOSHIBA CORPORATION: OPERATING SEGMENTS
  • TABLE 82. TOSHIBA CORPORATION: PRODUCT PORTFOLIO
  • TABLE 83. TOSHIBA CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. BIO-RAD LABORATORIES INC: KEY EXECUTIVES
  • TABLE 85. BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT
  • TABLE 86. BIO-RAD LABORATORIES INC: OPERATING SEGMENTS
  • TABLE 87. BIO-RAD LABORATORIES INC: PRODUCT PORTFOLIO
  • TABLE 88. BIO-RAD LABORATORIES INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. LIFE SIGN LLC: KEY EXECUTIVES
  • TABLE 90. LIFE SIGN LLC: COMPANY SNAPSHOT
  • TABLE 91. LIFE SIGN LLC: OPERATING SEGMENTS
  • TABLE 92. LIFE SIGN LLC: PRODUCT PORTFOLIO
  • TABLE 93. LIFE SIGN LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. SCHILLER AG: KEY EXECUTIVES
  • TABLE 95. SCHILLER AG: COMPANY SNAPSHOT
  • TABLE 96. SCHILLER AG: OPERATING SEGMENTS
  • TABLE 97. SCHILLER AG: PRODUCT PORTFOLIO
  • TABLE 98. SCHILLER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. BECKMAN COULTER,INC.: KEY EXECUTIVES
  • TABLE 100. BECKMAN COULTER,INC.: COMPANY SNAPSHOT
  • TABLE 101. BECKMAN COULTER,INC.: OPERATING SEGMENTS
  • TABLE 102. BECKMAN COULTER,INC.: PRODUCT PORTFOLIO
  • TABLE 103. BECKMAN COULTER,INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. GE HEALTHCARE: KEY EXECUTIVES
  • TABLE 105. GE HEALTHCARE: COMPANY SNAPSHOT
  • TABLE 106. GE HEALTHCARE: OPERATING SEGMENTS
  • TABLE 107. GE HEALTHCARE: PRODUCT PORTFOLIO
  • TABLE 108. GE HEALTHCARE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. HITACHI MEDICAL SYSTEMS: KEY EXECUTIVES
  • TABLE 110. HITACHI MEDICAL SYSTEMS: COMPANY SNAPSHOT
  • TABLE 111. HITACHI MEDICAL SYSTEMS: OPERATING SEGMENTS
  • TABLE 112. HITACHI MEDICAL SYSTEMS: PRODUCT PORTFOLIO
  • TABLE 113. HITACHI MEDICAL SYSTEMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 115. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 116. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 117. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 118. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 120. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 121. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 122. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 123. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL HEART ATTACK DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL HEART ATTACK DIAGNOSTICS MARKET
  • FIGURE 3. SEGMENTATION HEART ATTACK DIAGNOSTICS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN HEART ATTACK DIAGNOSTICS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHEART ATTACK DIAGNOSTICS MARKET
  • FIGURE 11. HEART ATTACK DIAGNOSTICS MARKET SEGMENTATION, BY BY TYPE
  • FIGURE 12. HEART ATTACK DIAGNOSTICS MARKET FOR ELECTROCARDIOGRAM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. HEART ATTACK DIAGNOSTICS MARKET FOR BLOOD TESTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. HEART ATTACK DIAGNOSTICS MARKET FOR ANGIOGRAM, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. HEART ATTACK DIAGNOSTICS MARKET FOR COMPUTERIZED CARDIAC TOMOGRAPHY, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. HEART ATTACK DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. HEART ATTACK DIAGNOSTICS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 18. HEART ATTACK DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. HEART ATTACK DIAGNOSTICS MARKET FOR DIAGNOSTICS CENTERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. HEART ATTACK DIAGNOSTICS MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: HEART ATTACK DIAGNOSTICS MARKET
  • FIGURE 27. TOP PLAYER POSITIONING, 2024
  • FIGURE 28. BIONET CO., LTD: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. BIONET CO., LTD: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. BIONET CO., LTD: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. TOSHIBA CORPORATION: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. TOSHIBA CORPORATION: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. TOSHIBA CORPORATION: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. BIO-RAD LABORATORIES INC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. BIO-RAD LABORATORIES INC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. BIO-RAD LABORATORIES INC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. LIFE SIGN LLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. LIFE SIGN LLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. LIFE SIGN LLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. SCHILLER AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. SCHILLER AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. SCHILLER AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. BECKMAN COULTER,INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. BECKMAN COULTER,INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. BECKMAN COULTER,INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. GE HEALTHCARE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. GE HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. GE HEALTHCARE: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. HITACHI MEDICAL SYSTEMS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. HITACHI MEDICAL SYSTEMS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. HITACHI MEDICAL SYSTEMS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Heart Attack Diagnostics Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved